CClinicalTrials.gg
RecruitingNCT06626490PREMOUpdated May 1, 2026

Prospective Follow-up of the Prevision Hip Stem With Comparison of Different Implant Variants

An observational study in Revision Total Hip Arthroplasty and Periprosthetic Fracture of Hip, sponsored by Aesculap AG. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Aesculap AG · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Study summary

The study design is confirmative for non-inferiority of the functional outcome of the implants and is intended to examine the safety and performance of the Prevision hip stem. The study is an observational post-market clinical follow-up study, and the study sites chose the stem variant depending on their own routine and indication.

Read the detailed description

Generally, the advantage of the Prevision implant family is that all implant variants can be implanted with basically the same instrumentation, which makes it easier to switch to another variant. All implant variants will be available at the study sites and switching between the variants in the study will be encouraged.

The aim of the study is to prove the non-inferiority of the OHS functional outcome after two years to the predecessor implant generation, and comparable revision hip stems. In addition, the patient groups treated with the different variants, and outcome of these subgroups will be descriptively compared.

02

Conditions studied

  • Revision Total Hip Arthroplasty
  • Periprosthetic Fracture of Hip

Keywords

  • Patient-reported outcomes
  • Clinical performance and safety
  • Total hip arthroplasty implantation
03

In context

Lead sponsor

Aesculap AG is the lead sponsor of 104 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with indication of a hip revision

Inclusion criteria

  • Revision hip arthroplasty patients treated with a Prevision hip stem
  • Written patient informed consent
  • Patients are able to attend at follow-up examinations

Exclusion criteria

Exclusion Criteria:

  • Patients \< 18 years at surgery
  • Pregnancy at implantation
  • Patients held in a custodial setting
  • Patients in a relationship of dependence on the sponsor, the clinic or the investigator
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
120 participants (estimated)
Patient registry
No

Interventions

  • DevicePrevision Revision hip endoprosthesis stem implantation

    The Prevision hip endoprosthetic stem is a femoral part of a hip joint endoprosthesis. The system provides cementless and cemented variants. Prevision hip stems are modular with a short proximal and longer distal component, or monobloc hip stems. Modular components are coupled via a Prevision specific conical connection with a torque wrench and a tension nut to apply a predefined torsional moment on the connection. The distal component of modular Prevision stems can be combined with locking screws for additional bone fixation. Both types, the monobloc and the modular, provide a 12/14 taper that serves as a connection for metal or ceramic prosthesis heads. Prevision hip stems are combined at the acetabulum with a cementless or cemented acetabular cup.

06

What researchers measure

Primary outcomes

  1. Functional outcome of the hip revision surgery

    Oxford Hip Score:The Oxford Hip Score (OHS) is a joint-specific, patient-reported outcome measure designed to assess disability in patients undergoing total hip replacement (THR)

    Time frame: after two years

Secondary outcomes

  1. Kaplan-Meier survival

    Kaplan-Meier Analysis is a standard statistical method to describe the survival of human subjects or medical products over a defined time period. The revision-free survival rate is the performance indicator of the product under investigation and confirms the clinical outcome of the knee prosthesis. Information on survival of the implant will be collected until the last follow-up of the study patients took place. 1. revision for any reason 2. hip stem revision 3. aseptic hip stem revision

    Time frame: after two years

  2. EQ-5D-5L Quality of Life

    EQ-5D is a standardized 5-dimension 5-level measure of the health status and is developed by the EuroQol Group in order to have a simple and generic measure for clinical and economic assessment. Instructions for the user are directly included into the questionnaire and it consists of two pages. One cover five different dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression) and the other one the EQ visual Analogue Scale (EQ-VAS). The VAS scale records the self rated health status of the patient from the level "the worst health you can imagine" to "the best health you can imagine".

    Time frame: visits after 2 and 5 years

  3. Complications

    Time frame: visits after 2 and 5 years

  4. Patient satisfaction

    Patient reported four-scale evaluation: * very satisfied * satisfied * unsatisfied * very unsatisfied

    Time frame: visits after 2 and 5 years

  5. Pain (VAS Score)

    VAS Pain at Rest: 0-100, lower is better VAS Pain under load: 0-100, lower is better Patients are asked to mark a point on the line that corresponds to their current level of pain. This mark is then measured and converted into a numerical value, usually between 0 and 10 or 0 and 100, where 0 indicates no pain and the highest value indicates the most severe pain

    Time frame: visits after 2 and 5 years

  6. Radiology: Hip stem subsidence

    Hip stem subsidence in mm.

    Time frame: visits after 2 and 5 years

  7. Qualitative radiologic assessment

    Fracture healing; if radiolucent line \> 2 mm, resorption, hypertrophy, cyst

    Time frame: visits after 2 and 5 years

07

Study locations

2 of 2 sites recruiting
  • Orthopädische Kliniken im Annastift, MHH, Anna-von-Borries-Str. 1-7
    Hanover, 30625, Germany
    • Henning Windhagen, Prof. Dr. · Contact
    Recruiting
  • Hinchingbrooke Hospital
    Huntingdon, Cambridgeshire PE29 6NT, United Kingdom
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06626490
Lead sponsor
Aesculap AG
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Apr 7, 2026
Primary completion
Mar 2033 (estimated)
Completion
Mar 2034 (estimated)
Last update
May 1, 2026

Study contacts

Kerstin Bergmann
Contact
studies@aesculap.de
+49746195- ext. 0
Lutz Dreyer, Dr.
Contact
studies@aesculap.de
+49746195- ext. 0
Henning Windhagen, Prof. Dr.
principal investigator · Orthopädische Kliniken im Annastift, MHH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion